Literature DB >> 35916253

Mycobacterium paragordonae is an emerging pathogen in human pulmonary disease: clinical features, antimicrobial susceptibility testing and outcomes.

Yuanchun Li1, Wenping Zhang1, Jing Zhao2, Wenjie Lai1, Yanlin Zhao3, Yanming Li4, Jiuxin Qu1.   

Abstract

OBJECTIVES: Mycobacterium paragordonae (MPG) is an emerging and less common type of Non-tuberculous mycobacteria (NTM) and we know little about its characteristics and prognosis, hence we constructed this retrospective cohort study.
METHODS: MPG was identified using MALD-TOF MS, multi-target combined gene sequencing and WGS. Clinical information was collected, antimicrobial susceptibility testing was measured using the SLOMYCO panel, and optimal growth temperature testing was measured using Lowenstein-Jensen medium.
RESULTS: Eight MPGs were isolated from 1730 NTMs (0.46%); the mean age of MPG pulmonary disease (MPG-PD) patients was 42.38 ± 9.92 years, 37.5% were male, and the average BMI was 18.4 ± 0.51 kg/m2. All patients had the symptoms of cough and sputum and CT images mainly presented in patchy or streaky shadows, MPG grew at 25°C, 30°C and 37°C, and the optimal growth temperature is 37°C. MPGs were sensitive to clarithromycin, rifabutin, amikacin, linezolid, moxifloxacin, cotrimoxazole and ciprofloxacin, two isolates were resistant to rifampicin. Two patients had follow up information, their imaging remained stable during the follow-up.
CONCLUSIONS: MPG-PD is a rare NTM disease and is more likely to develop in middle-aged, female, and low BMI patients. The patients present with no specific features within the symptoms as well as the CT imaging. The optimal growth temperature of MPG is at 37°C, MPG-PD has excellent sensitivity to drugs recommended by CLSI and presents with a stable disease.

Entities:  

Keywords:  Mycobacterium paragordonae; antimicrobial susceptibility testing; clinical features; outcomes; pulmonary disease

Mesh:

Substances:

Year:  2022        PMID: 35916253      PMCID: PMC9364734          DOI: 10.1080/22221751.2022.2103453

Source DB:  PubMed          Journal:  Emerg Microbes Infect        ISSN: 2222-1751            Impact factor:   19.568


  21 in total

1.  Molecular characterization of nontuberculous mycobacteria in hospital waters: a two-year surveillance study in Tehran, Iran.

Authors:  Somayeh Moradi; Mohammad Javad Nasiri; Fazel Pourahmad; Davood Darban-Sarokhalil
Journal:  J Water Health       Date:  2019-04       Impact factor: 1.744

2.  International Committee on Systematic Bacteriology: announcement of the report of the ad hoc Committee on Reconciliation of Approaches to Bacterial Systematics.

Authors:  L G Wayne
Journal:  Zentralbl Bakteriol Mikrobiol Hyg A       Date:  1988-06

3.  Mycobacterium paragordonae: a rare cause of peritonitis in a peritoneal dialysis patient.

Authors:  Chi Yuen Cheung; Naomi Hua Yin Cheng; Wan Man Ting; Wai Leung Chak
Journal:  Clin Nephrol       Date:  2017-12       Impact factor: 0.975

4.  Mycobacterium paragordonae sp. nov., a slowly growing, scotochromogenic species closely related to Mycobacterium gordonae.

Authors:  Byoung-Jun Kim; Seok-Hyun Hong; Yoon-Hoh Kook; Bum-Joon Kim
Journal:  Int J Syst Evol Microbiol       Date:  2013-09-04       Impact factor: 2.747

5.  Mycobacterium gordonae infection in immunocompromised and immunocompetent hosts: A series of seven cases and literature review.

Authors:  Hao-Yun Chang; Wan-Chen Tsai; Tai-Fen Lee; Wang-Huei Sheng
Journal:  J Formos Med Assoc       Date:  2020-07-04       Impact factor: 3.282

6.  Pseudo-outbreak of Mycobacterium paragordonae in a hospital: possible role of the aerator/rectifier connected to the faucet of the water supply system.

Authors:  I Takajo; C Iwao; M Aratake; Y Nakayama; A Yamada; N Takeda; Y Saeki; K Umeki; T Toyama; Y Hirabara; M Fukuda; A Okayama
Journal:  J Hosp Infect       Date:  2019-11-28       Impact factor: 3.926

7.  Mycobacterium gordonae in Patient with Facial Ulcers, Nosebleeds, and Positive T-SPOT.TB Test, China.

Authors:  Yanqing Chen; Juan Jiang; Haiqin Jiang; Jun Chen; Xiaopo Wang; Weida Liu; Zhiming Chen; Ying Shi; Wenyue Zhang; Hongsheng Wang
Journal:  Emerg Infect Dis       Date:  2017-07       Impact factor: 6.883

8.  Studies of antimicrobial resistance in rare mycobacteria from a nosocomial environment.

Authors:  Sónia Gonçalves Pereira; Susana Alarico; Igor Tiago; Diogo Reis; Daniela Nunes-Costa; Olga Cardoso; Ana Maranha; Nuno Empadinhas
Journal:  BMC Microbiol       Date:  2019-03-19       Impact factor: 3.605

9.  Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.

Authors:  Charles L Daley; Jonathan M Iaccarino; Christoph Lange; Emmanuelle Cambau; Richard J Wallace; Claire Andrejak; Erik C Böttger; Jan Brozek; David E Griffith; Lorenzo Guglielmetti; Gwen A Huitt; Shandra L Knight; Philip Leitman; Theodore K Marras; Kenneth N Olivier; Miguel Santin; Jason E Stout; Enrico Tortoli; Jakko van Ingen; Dirk Wagner; Kevin L Winthrop
Journal:  Clin Infect Dis       Date:  2020-08-14       Impact factor: 9.079

10.  Potential of recombinant Mycobacterium paragordonae expressing HIV-1 Gag as a prime vaccine for HIV-1 infection.

Authors:  Byoung-Jun Kim; Bo-Ram Kim; Yoon-Hoh Kook; Bum-Joon Kim
Journal:  Sci Rep       Date:  2019-10-29       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.